Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2014 · 10-Q
Revenue$855.00K$855.00K−17.4% vs Q2 2013 Net Income-$9.52M-$9.52MN/M vs Q2 2013 EPS Diluted-$0.16-$0.16N/M vs Q2 2013 Gross Profit$855,435−17.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$10,777,978N/M Free Cash Flowderived-$10,950,706N/M Margins · derivedGross margin100.1%+0.1 pt vs Q2 2013
Operating margin-1527.7%−743.9 pt vs Q2 2013
Net margin-1113.5%−384.4 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 11, 2014 · 42 d after period end